Want to see TSE:BPC full AI Analyst Report?
Top Page
Pangea Natural Food, Inc.
(BPC)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.37
▼(-19.13% Downside)
Action:Reiterated
Date:08/25/26
The score is primarily constrained by weak financial performance—severe losses, negative margins, and persistent (accelerating) cash burn alongside equity instability. Technicals add modest pressure with a below-moving-average downtrend and negative MACD, partially offset by near-term oversold signals. Corporate updates are positive but early-stage, and valuation is difficult to support given negative earnings and no dividend yield provided.
Positive Factors
2025 Revenue Growth
The sharp 2025 revenue increase indicates that the company found a path to materially higher sales, expanding its commercial opportunity. If this scale can be retained, it may provide a broader base for operating leverage and future product or platform development.
Negative Factors
Severe Unprofitability
Deeply negative gross and net margins show that the recent revenue expansion has not translated into viable economics. Persistent losses weaken the company’s ability to self-fund growth and indicate that substantial operational improvement is needed before higher sales can create durable shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Growth
The sharp 2025 revenue increase indicates that the company found a path to materially higher sales, expanding its commercial opportunity. If this scale can be retained, it may provide a broader base for operating leverage and future product or platform development.
Read all positive factors
Pangea Natural Food, Inc. (BPC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$17.00M
Dividend YieldN/A
Average Volume (3M)109.56K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth2292.02%
EPS Growth-62.06%
CountryCA
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryRestaurants
Share Statistics
EPS (TTM)-0.19
Shares Outstanding43,586,210
10 Day Avg. Volume76,117
30 Day Avg. Volume109,565
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.48
Price to Sales (P/S)196.00
P/FCF Ratio-4.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pangea Natural Food, Inc. Business Overview & Revenue Model
Company Description
The Precision Peptide Company Inc. manufactures and distributes plant-based patties and other food products in Canada. The company offers old fashioned ghee; energy gel; and plant-based patty; energy gel products, and munchie mix, as well as custo...
Pangea Natural Food, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Oct 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.72K | 12.20K | 285.59K | 580.99K | 68.50K |
| Gross Profit | -69.17K | 6.91K | -32.79K | 40.97K | -67.25K |
| EBITDA | -2.16M | -917.21K | -1.64M | -855.30K | -172.28K |
| Net Income | -4.53M | -1.03M | -1.66M | -1.13M | -173.19K |
Balance Sheet | |||||
| Total Assets | 1.33M | 182.29K | 191.72K | 620.34K | 1.34M |
| Cash, Cash Equivalents and Short-Term Investments | 960.01K | 140.09K | 51.64K | 75.95K | 807.57K |
| Total Debt | 0.00 | 17.83K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 401.26K | 732.74K | 330.00K | 408.57K | 116.82K |
| Stockholders Equity | 929.72K | -550.45K | -138.28K | 211.76K | 1.23M |
Cash Flow | |||||
| Free Cash Flow | -2.33M | -439.41K | -980.68K | -725.80K | -590.75K |
| Operating Cash Flow | -2.33M | -439.41K | -980.68K | -718.60K | -529.76K |
| Investing Cash Flow | -270.17K | 0.00 | 0.00 | -7.20K | -60.98K |
| Financing Cash Flow | 3.40M | 527.86K | 956.37K | -1.32K | 1.40M |
Pangea Natural Food, Inc. Technical Analysis
Negative
0.46
Price Trends
0.44
Negative
0.46
Negative
0.40
Negative
Market Momentum
-0.02
Positive
31.48
Neutral
21.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BPC, the sentiment is Negative. The current price of 0.46 is above the 20-day moving average (MA) of 0.42, above the 50-day MA of 0.44, and above the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.48 is Neutral, neither overbought nor oversold. The STOCH value of 21.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BPC.
Pangea Natural Food, Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | C$30.90M | -20.35 | 30.14% | ― | 32.91% | 55.73% | |
46 Neutral | C$1.32M | -0.79 | 30.06% | ― | -3.70% | 51.27% | |
41 Neutral | C$17.00M | -2.25 | -162.93% | ― | 2292.02% | -62.06% | |
25 Underperform | C$61.76M | -24.03 | 81.87% | ― | ― | ― |
* Consumer Defensive Sector Average
TSE:BPC
Pangea Natural Food, Inc.
0.36
-0.09
-20.00%
TSE:ISTK
Good Flour Corp
0.43
-2.20
-83.78%
TSE:BITE
Blender Bites
0.15
0.00
0.00%
TSE:MEAT
Modern Meat
0.07
-0.11
-61.11%
TSE:NPRA
Nepra Foods
0.23
0.09
64.29%
Pangea Natural Food, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Orders First Commercial Run of Thymosin Alpha-1 Patch
Positive
Oct 7, 2026
The Precision Peptide Company has ordered 20,000 units of its needle-free Thymosin Alpha-1 transdermal patch ahead of a planned commercial launch. Each U.S.-manufactured patch is formulated to deliver 2 mg of the immune-modulating peptide, moving ...
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Company Opens U.S. Wholesale Channel for Needle-Free Wellness Products
Positive
Sep 29, 2026
The Precision Peptide Company has launched a U.S. wholesale program for its non-prescription, needle-free patches and supplements, opening distribution to gyms, fight academies, longevity clinics, med spas, physio and chiropractic practices, and s...
Business Operations and Strategy
Precision Peptide Company Sponsors Mental Health Boxing Event to Expand Combat Sports Reach
Positive
Sep 22, 2026
The Precision Peptide Company has become a strategic sponsor of Championing Mental Health 3, a professional boxing event promoted by Bash Boxing and scheduled for September 26, 2026, at Commerce Casino in California. The event will be broadcast on...
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Company Advances Thymosin Alpha-1 Patch in U.S. Testing
Positive
Sep 8, 2026
The Precision Peptide Company has advanced its Thymosin Alpha-1 transdermal patch into formal testing in the United States, aiming to complete the program by the second half of 2026 and move toward commercial production if results are satisfactory...
Business Operations and Strategy
Precision Peptide Company Grants RSUs and Stock Options to Consultant
Positive
Sep 5, 2026
The Precision Peptide Company Inc. has authorized the grant of 150,000 restricted share units and 200,000 incentive stock options to a company consultant under its omnibus share incentive plan. Each option allows the purchase of one common share a...
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Expands U.S. Rollout With FitExpo Anaheim Showcase
Positive
Aug 25, 2026
The Precision Peptide Company will showcase and sell its supplement range at FitExpo Anaheim on August 29–30, 2026, marking a step in its transition from purely online direct-to-consumer sales to live retail engagement with fitness and welln...
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Plans Needle-Free Tirzepatide Patch for Expanding GLP-1 Market
Positive
Aug 19, 2026
The Precision Peptide Company Inc. announced it is developing a tirzepatide-based transdermal patch in the U.S. as an addition to its peptide-focused product portfolio. The patch is designed to deliver the dual GIP/GLP-1 agonist through the skin, ...
Business Operations and StrategyProduct-Related Announcements
Precision Peptide Company Consolidates Amino Innovations Storefront Into Its Own Platform
Positive
Aug 7, 2026
The Precision Peptide Company has completed the migration of the Amino Innovations online supplement store, including its seven-product catalogue and existing customer base, onto its own e-commerce site. As a result, sales through the legacy Amino...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.